IP Library Granted Patent US 10,239,956
Granted Patent B2
US 10,239,956 · App. 15/645,041 · Granted Mar 26, 2019

Nucleic acid encoding bone marrow stromal antigen 1 antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,239,956
App. No.
15/645,041
Granted
Mar 26, 2019
Kind
B2
Abstract

The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.

Claims (12)

1. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody variable region, wherein the antibody variable region comprises SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:46, or SEQ ID NO:49.

2. The isolated nucleic acid of claim 1 , wherein the antibody variable region comprises SEQ ID NO:2.

3. The isolated nucleic acid of claim 1 , wherein the antibody variable region comprises SEQ ID NO:4.

4. The isolated nucleic acid of claim 1 , wherein the antibody variable region comprises SEQ ID NO:46.

5. The isolated nucleic acid of claim 1 , wherein the antibody variable region comprises SEQ ID NO:49.

6. An isolated nucleic acid comprising a nucleotide sequence comprising SEQ ID NO:6, or SEQ ID NO:8.

7. The isolated nucleic acid of claim 6 , wherein the nucleotide sequence comprises SEQ ID NO:6.

8. The isolated nucleic acid of claim 6 , wherein the nucleotide sequence comprises SEQ ID NO:8.

9. An isolated host cell containing the nucleic acid of claim 1 .

10. An isolated host cell containing the nucleic acid of claim 6 .

11. A method of making an antibody comprising culturing a host cell according to claim 9 under conditions where an antibody, or antigen binding portion thereof, is expressed and isolating the antibody, or antigen binding portion thereof.

12. A method of making an antibody comprising culturing a host cell according to claim 10 under conditions where an antibody, or antigen binding portion thereof, is expressed and isolating the antibody, or antigen binding portion thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 26, 2021
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: OXFORD BIOTHERAPEUTICS INC.
Reel/Frame 055026/0720 →
RELEASE OF SECURITY INTEREST Recorded Jan 26, 2021
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: OXFORD BIOTHERAPEUTICS INC.; OXFORD BIOTHERAPEUTICS LTD.
Reel/Frame 055027/0606 →
SECURITY INTEREST Recorded Aug 28, 2019
From: OXFORD BIOTHERAPEUTICS INC.; OXFORD BIOTHERAPEUTICS LTD.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050197/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2017
From: ROHLFF, CHRISTIAN; TERRETT, JONATHAN ALEXANDER
To: OXFORD BIOTHERAPEUTICS LTD
Reel/Frame 042978/0570 →